《抗体药物研发与产业化进展》

&《Novel antibody therapeutics for cancer (YZY Biopharma)》

 主讲人：周鹏飞博士

CEO 首席执行官  武汉友芝友生物制药有限公司

华中科技大学同济药学院客座教授

武汉东湖高新区第四批“3551人才”

时间：2012年12月6日 周四 2:30-5:00pm

地点：东12楼402

周鹏飞博士有十余年肿瘤免疫治疗性抗体药物研发经验，在肿瘤生物学及肿瘤免疫治疗上有独到的建树。曾任中美冠科技术有限公司（Crown Bioscience Inc.）免疫学总监，辉瑞-冠科亚洲肿瘤研发中心执行总监。周鹏飞博士本科与研究生阶段就读于同济医科大学，于2005年获得加拿大麦克马斯特大学（McMaster University）分子免疫学博士学位，随后在美国斯坦福大学医学院肿瘤中心以及美国仙灵宝雅（Schering-Plough）从事博士后研究工作，并发表学术论文30余篇。

Pengfei Zhou, PhD/MD, Chief Executive Officer, YZY Biopharma Co., LTD. Guest Professor, Tongji Medical college, HUST.

Dr. Zhou has over a decade of experience in drug R&D. Prior to co-founding YZY Biopharma, he was the executive director of Immunology, Crown Bioscience Inc., a leading CRO company dedicated to translational oncology. Dr. Zhou has extensive and in-depth experience in cancer biology and immunology. Dr. Zhou started his career as a surgeon in oncology and then postdoctoral scientist in immunology at Stanford University and Schering-Plough (currently Merck Laboratories). Dr. Zhou obtained his PhD in molecular immunology from McMaster University, Canada, and BS degree in medicine and MS degree in surgery (pediatric oncology) from Tongji Medical University, Wuhan China. Dr. Zhou has authored more than 30 publications and abstracts in immunology and oncology.